For transplant patients, waiting days for blood test results can mean the difference between timely treatment and dangerous complications. Under the direction of Co-Founder and CEO Corentin Gondrand, QuantiLight is eliminating that wait, delivering lab-grade results in just 15 minutes, right at the point of care. Fueled by bioluminescent sensor technology from the Max Planck Institute for Medical Research, the Heidelberg-based startup is addressing delays in therapeutic drug monitoring (TDM) that affect millions of patients worldwide. Backed by clinical proof-of-concept and advancing toward CE-IVD and FDA submissions, QuantiLight is on track to transform diagnostic workflows for transplant patients and beyond.
QuantiLight was founded by Corentin Gondrand and Estelle Bonedeau, inspired by the potential to bring central-lab precision to wherever patients are. “We saw the opportunity to transform how lab-quality blood testing could be delivered, making it possible anywhere, anytime, without compromising precision,” Gondrand explained.
The company’s foundation lies in pioneering work at the Max Planck Institute for Medical Research. Gondrand and Bonedeau translated that research into a commercial strategy, uniting scientific depth with a vision for scalable impact.
For Gondrand, the inspiration was personal and urgent. “In transplantation and other chronic conditions, delayed lab results can be the difference between a timely intervention and a missed opportunity. The moment I realized our technology could provide central-lab accuracy in about 15 minutes, right at the point of care, I knew we had to build the company,” he said.
Current diagnostic models still depend on venous blood draws, centralized laboratories, and turnaround times of two to three days. In that gap, clinicians are often forced to make treatment decisions without all the data they need, a delay that can trigger complications, extend hospital stays, and drive up costs. The scale of the challenge is significant. In transplantation alone, more than 1.5 million patients in Europe and the United States require frequent monitoring, sometimes over 40 tests each year. And the pressure on diagnostic systems is only set to grow: KPMG forecasts that by 2030, the number of people living with three or more chronic conditions will nearly triple.
QuantiLight is positioning itself as a timely alternative, offering lab-grade results to the physician in about 15 minutes.
At the heart of QuantiLight’s platform is its patented bioluminescent sensor technology, which eliminates the need for external excitation light sources.
“The sensors are designed to recognize specific molecules, for example, immunosuppressant drugs like tacrolimus, and emit light in response,” Gondrand explained. That signal is captured by the compact device, quantified with lab-level accuracy, and transmitted securely to the clinician.
The workflow is intentionally simple:
Because the architecture is modular, the platform can expand rapidly to include additional analytes, from biologics to mood stabilizers to liver and kidney function biomarkers. “We combine the precision of a central lab with the speed and convenience of true point-of-care testing,” Gondrand said.
Unlike many rapid tests, QuantiLight’s platform is highly specific, repeatable, and designed for integration into existing reimbursement codes, making adoption easier for providers.
QuantiLight has already cleared several proof-of-concept hurdles:
Looking ahead:
Gondrand has been selected to present on the Presenting Company Stage 2 at LSI Europe ’25, scheduled for Wednesday, September 10th, from 11:45 AM to 11:54 AM. Join us in welcoming him to the event in London, where he will share the latest updates on QuantiLight’s technology and development.
Schedule an exploratory call
Request Info17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2025 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy